Topiramate use broadened

The licensed indications for topiramate (Topamax) in the UK have been broadened to ensure consistency with other European countries.

In epilepsy, Topamax monotherapy is now indicated for long-standing (as well as newly diagnosed) epilepsy and adjunctive therapy is no longer restricted to patients who are inadequately controlled on conventional first-line agents.

In migraine, treatment can now be initiated outside specialist care and no longer requires six-monthly review. In addition, prophylactic use of the drug can be considered regardless of the number and severity of migraines.

View Topamax drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more